A Subcutaneously Administered Investigational RNAi Therapeutic, Fitusiran (ALN-AT3), Targeting Antithrombin for Treatment of Hemophilia: Interim Results in Patients with Hemophilia A or B

Authors
Category Primary study
ConferenceHaemophilia
Year 2016
This article has no abstract
Epistemonikos ID: 0cb71dd6becdc31062b94c4df94ff5673d3433c3
First added on: Apr 29, 2026